Back to Journals
Journal of Hepatocellular Carcinoma
Aims and Scope
The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access, online journal.
Primary liver tumors, primarily hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide, with around 750,000 new cases annually, with around 700,000 deaths. 80% occurs in the developing world, in which the incidence is beginning to decline, due to HBV vaccination and developments in food hygiene; with an increasing incidence in the developed world, partly due to metabolic syndrome, obesity and diabetes. There are major variations in geographic incidence and gender susceptibility.
We offer the international community a platform for the dissemination and study of clinical, translational and basic research findings in this rapidly developing field. Exciting developments in the areas of epidemiology, vaccination, hepatitis therapy, pathology, molecular tumor classification and prognostication, new radiological techniques, amazing new classes of targeted medical therapies and a resultant vast increase in the associated clinical trials and reports are all a needed part of a new journal focusing on hepatobiliary tumors.
We consider the following categories of article for publication: Clinical practice, clinical trial or research articles, editorials, reviews, case series, case reports and new study methods.
Areas of interest: Basic HCC-related research in vivo or in vitro; clinical and translational research; cell signalling pathway research; clinical trials; new drugs or other therapies, combination drug and primary therapy reports; new radiology approaches; new clinical pathology techniques and results; epidemiology, surveillance and prevention; carcinogenesis; dietary aspects of carcinogenesis, tumor biology and clinical results; psycho-social aspects of hepato-biliary tumors and quality of life issues.
As of 1st April 2019, the Journal of Hepatocellular Carcinoma will no longer consider meta-analyses for publication.